News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Clearside Biomedical Announces First Successful Human Dosing in a Safety and Tolerability Study in Patients With Retinal Disease


11/6/2012 10:01:18 AM

ATLANTA--(BUSINESS WIRE)--Clearside Biomedical, Inc., a privately held company specializing in the research and development of ophthalmic pharmaceuticals, today announced the successful dosing of patients in a safety and tolerability clinical study using its proprietary ocular microinjection platform to deliver therapeutics to treat retinal disease.

Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES